Document Detail


Statin therapy--Part II: Clinical considerations for cardiovascular disease.
MedLine Citation:
PMID:  20547576     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are the medical treatment of choice for hypercholesterolemia. In addition to achieving a therapeutic decrease in serum cholesterol levels, statin therapy appears to promote pleiotropic effects that are independent of changes in serum cholesterol. These cholesterol lowering and pleiotropic effects are beneficial not only for the coronary circulation, but for the myocardium and peripheral arterial system as well. Patients receiving statin therapy must be carefully monitored, however, as statins potentially have harmful side effects and drug interactions. This article is part II of a 2-part review, and it focuses on the clinical aspects of statin therapy in cardiovascular disease.
Authors:
Benjamin Sadowitz; Keri Seymour; Michael J Costanza; Vivian Gahtan
Related Documents :
9105566 - A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlip...
11675906 - Cerivastatin induces carotid artery plaque stabilization independently of cholesterol l...
8900336 - Lipid management: current diet and drug treatment options.
19332196 - Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to lo...
21545076 - Effects of long-term supplementation of dairy cow diets with rumen-protected conjugated...
18824186 - The role of androgens in the mediation of seasonal territorial aggression in male siber...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review     Date:  2010-06-14
Journal Detail:
Title:  Vascular and endovascular surgery     Volume:  44     ISSN:  1938-9116     ISO Abbreviation:  Vasc Endovascular Surg     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-09-16     Completed Date:  2011-01-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101136421     Medline TA:  Vasc Endovascular Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  421-33     Citation Subset:  IM    
Affiliation:
Division of Vascular Surgery and Endovascular Services, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aortic Diseases / drug therapy
Cardiovascular Diseases / drug therapy*
Cerebrovascular Disorders / drug therapy
Coronary Artery Disease / drug therapy
Drug Interactions
Heart Failure / drug therapy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  therapeutic use*
Peripheral Arterial Disease / drug therapy
Risk Assessment
Treatment Outcome
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Setting the standards for reporting ruptured abdominal aortic aneurysm.
Next Document:  Newspaper coverage about smoking in leading Chinese newspapers in past nine years.